ANNOVIS BIO ANNOUNCES PATIENT ENROLLMENT UPDATE FOR PHASE 3 STUDY OF BUNTANETAP FOR THE TREATMENT OF PARKINSON’S DISEASE

ANNOVIS BIO ANNOUNCES PATIENT ENROLLMENT UPDATE FOR PHASE 3 STUDY OF BUNTANETAP FOR THE TREATMENT OF PARKINSON’S DISEASE
Buntanetap is a highly differentiated and potentially ground-breaking therapy that has been designed to inhibit the production of multiple neurotoxic proteins which are associated with several ... read more
Source: Bing NewsPublished on 2023-01-24